PHOENIX, February 19, 2021 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced that Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx, will give an online presentation on February 23rd at 2 pm PST at Biocom’s 11th Annual Global Life Sciences Partnering Conference. After the presentation, OncoMyx will be available at a virtual networking table for additional Q&A.
OncoMyx’s presentation will be accessible on demand during the event for all registered attendees. Event registration is available at https://biocomglobalpartnering.org/.
OncoMyx was founded on breakthrough research demonstrating the myxoma virus is highly immuno-interactive and can selectively infect and kill a broad range of cancer cell types. As a virus that is nonpathogenic to humans, myxoma does not have to overcome pre-existing immunity. With a large genome, myxoma is ideal for multi-arming, creating a precision medicine approach with a unique oncolytic virus that can activate the cancer immunity cycle and expand the therapeutic effectiveness of immunotherapies.
About OncoMyx Therapeutics
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have the potential to be a safe and effective complement to immunotherapies. The company’s MYXV platform, exclusively licensed from Arizona State University and Western, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.